Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A.M. et al.
Editor's note
The triple agonist that has Lilly's competitors anxious. 24.2% mean weight loss at 48 weeks with the 12 mg dose — the largest non-surgical number anyone has seen. Phase 2, n=338, no plateau yet at week 48. Phase 3 results will decide whether the curve really keeps going.